All In Biotech

Free tool

FAERS Monitor: Mytesi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202292 or its brand name (Mytesi, Crofelemer). Reports on generic versions are filed under their own applications.

Reports

239

Serious

84

35% of reports

Hospitalization

33

Death reported

29

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use61
  • drug ineffective51
  • product dose omission issue29
  • diarrhoea26
  • death23
  • pain17
  • anxiety14
  • emotional distress14
  • anhedonia12
  • fatigue11
  • chronic kidney disease10
  • dizziness10
  • constipation9
  • depression8
  • osteoporosis8

Reports by year received

View as table
YearReports
20131
20141
20161
20173
20185
20195
20207
202114
202239
202343
202446
202540
202634

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,920 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anhedoniaSignal1240.223.2421
osteoporosisSignal817.18.7106
chronic kidney diseaseSignal1011.66.387
emotional distressSignal1410.26.1107
product dose omission issueSignal298.76.2192
off label useSignal616.14.9268
anxietySignal144.32.633
constipationSignal93.61.915
diarrhoeaSignal263.52.546
drug ineffectiveSignal513.42.790
depressionSignal83.11.69
painSignal172.41.513
deathSignal232.31.617
dizziness101.81.03
fatigue111.20.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.